Back

Optimal duration of dual antiplatelet therapy study after ACS.

16 October 2016 (12:07 - 12:30)
Organised by:
Congress Presentation Part of: Dilemmas in anti thrombotic therapy Antithrombotic agents ACVC Premium Access Acute Cardiovascular Care 2016

About the speaker

Photo
Professor Joao Morais

Polytechnic Institute of Leiria, Leiria (Portugal)

3 More presentations in this session

Presentation thumbnail
New tools to manage bleeding under NOACS.
Professor K. Huber (Vienna, AT)
Slides Video
Presentation thumbnail
To pre treat or not to pre treat in ACS?
Associate Professor S. Matetzky (Ramat Gan, IL)
Slides Video
Presentation thumbnail
Anti thrombotic choices after bleeding.
Professor S. Halvorsen (Oslo, NO)
Slides Video

Access the full session

Session thumbnail
Dilemmas in anti thrombotic therapy

The Event

Event poster

Acute Cardiovascular Care 2016

16 October 2016 12:07 CET
You may be interested in
thumbnail
Congress Presentation
When should prolonged antiplatelet regimens be considered?
26 August 2023
thumbnail
Congress Presentation
Less bleeding by omitting aspirin in non-ST-segment elevation acute coronary syndrome patients (LEGACY)
1 September 2025
thumbnail
Congress Session
State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?
14 March 2025
thumbnail
Congress Presentation
Thirty-days versus standard duration of dual antiplatelet treatment after percutaneous coronary interventions: a systematic review and meta-analysis
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources